8-K 1 form8k.htm VASCULAR SOLUTIONS INC 8-K 4-30-2014
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
 
FORM 8-K
 
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
 
Date of Report: April 30, 2014
(date of earliest event reported)
 
VASCULAR SOLUTIONS, INC.
(Exact name of registrant as specified in its charter)
 
Commission File Number: 0-27605
 
 
Minnesota
 
41-1859679
(State or other jurisdiction of incorporation)
 
(IRS Employer Identification No.)
 
6464 Sycamore Court North
Minneapolis, Minnesota 55369
(Address of principal executive offices)
 
 (763) 656-4300
(Registrant’s telephone number, including are code)
 
 Not Applicable
(Former name or former address, if changed since last report)
 
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
o Written communications pursuant to Rule 425 under Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act ( 17 CFR 240.13e-4(c))
Item 5.07.
Submission of Matters to a Vote of Security Holders.
 
At the Annual Meeting of Shareholders of Vascular Solutions, Inc. (the “Company”) held on April 30, 2014, the Company’s shareholders approved each of the following proposals, which were set forth in the Proxy Statement for the 2014 Annual Meeting of Shareholders:
 
Proposal 1
 
The Company’s shareholders elected each of the seven director nominees to a one-year term and until the director’s successor is elected and qualified (except in the case of earlier death, resignation or removal) as follows:
 
 
FOR
WITHHOLD
BROKER NON-VOTE
Martin Emerson
11,509,088
203,396
4,312,771
John Erb
10,925,551
786,933
4,312,771
Richard Kramp
11,643,955
  68,529
4,312,771
Richard Nigon
10,929,254
783,230
4,312,771
Paul O’Connell
10,928,251
784,233
4,312,771
Howard Root
10,927,364
785,120
4,312,771
Jorge Saucedo
11,642,398
  70,086
4,312,771

Proposal 2
 
The Company’s shareholders approved the Vascular Solutions, Inc. 2014 Qualified Performance-Based Compensation Plan:
 
FOR
AGAINST
ABSTAIN
BROKER NON-VOTE
10,517,987
1,180,356
14,141
4,312,771

Proposal 3
 
On an advisory basis, the Company’s shareholders approved the compensation of its named executive officers as described in the Compensation Discussion and Analysis section, and the other tabular and narrative disclosure regarding such compensation, set forth in the Proxy Statement for the 2014 Annual Meeting of Shareholders:
 
FOR
AGAINST
ABSTAIN
BROKER NON-VOTE
10,655,619
494,809
562,056
4,312,771

Proposal 4
 
The Company’s shareholders ratified the appointment of Baker Tilly Virchow Krause, LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2014:
 
FOR
AGAINST
ABSTAIN
BROKER NON-VOTE
15,201,366
817,852
6,037
0
SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 
VASCULAR SOLUTIONS, INC.
 
 
 
Date:  May 1, 2014
By:
/s/ James Hennen
 
 
James Hennen
 
 
Its: Chief Financial Officer